Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
about
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.Staging and prognostication of multiple myelomaTargeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingClonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapyDual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a Cereblon-independent manner.CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
P2860
Q27692033-7F62931D-98D5-4759-A406-8C5F3DF82CD1Q33846806-0A54C78B-6C96-4CC3-8BFD-197279DBCA3DQ33887173-65E5EF76-922E-4FBF-A21C-9031DA9A5189Q36306807-6C279042-1FA2-4E23-B067-2EC191F22FA4Q37505517-22B9ECDB-53F2-47E8-9D19-1869077ED239Q38183871-2B2DB283-59D4-426C-A586-58BCDC19B38FQ39560208-DF1B11CD-E00F-4501-9381-AE7508106697Q40424686-EA167BDD-8C6C-4399-BDE2-9A8C899684B6Q41346803-24D2AFD3-164F-4D93-9D66-9640EF0DA1D6Q41663752-8FD028C2-76DB-411F-B2A4-629853B49F0CQ42563529-B31CC6A2-9778-4890-868E-FAD7D1F6A209Q46275503-BD768D77-EA0E-49AE-BE2C-BC0427C42DE4Q49660927-C231D9D5-92C7-4715-ACC4-742E359963EDQ50057730-D9FACFEE-440C-4AAF-9D43-16F2F30C1AE5Q51753186-E76AAAD1-7CB1-4EB9-97F0-986E9FAC3492
P2860
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Extramedullary myeloma whole g ...... multi drug resistant disease.
@en
type
label
Extramedullary myeloma whole g ...... multi drug resistant disease.
@en
prefLabel
Extramedullary myeloma whole g ...... multi drug resistant disease.
@en
P2093
P2860
P356
P1476
Extramedullary myeloma whole g ...... multi drug resistant disease.
@en
P2093
A Keith Stewart
Ahmet Kurdoglu
Angela Baker
Chang-Xin Shi
David W Craig
Jan B Egan
Jessica Aldrich
Jessica Schmidt
John D Carpten
K Martin Kortuem
P2860
P304
P356
10.1111/BJH.12291
P407
P577
2013-03-11T00:00:00Z